Back to Agenda
Session 2: Global IDMP Implementation – Getting Closer to the Goal
Session Chair(s)
Nimesh Patel
Senior Director of Global Regulatory Systems , Eisai Co., Ltd., United States
The Identification of Medicinal Products (IDMP) offers a global framework for unique identification and consistent documentation of medicinal products, facilitating information exchange among regulators, manufacturers, suppliers, and distributors.
This session will present an overview of the testing results for the Global Pharmaceutical Product Identification (PhPID) Service operating model, which generates global PhPIDs for marketed medicinal products. The model's readiness for deployment, including its software functionality, interoperability, processes, and business rules will be discussed.
Malin Fladvad, Uppsala Monitoring Centre
Isabel Chicharo, European Medicines Agency
Flávia Moreira Cruz, ANVISA
Philipp Weyermann, Swissmedic
Vada Perkins, Boehringer Ingelheim
Karin Hay, Health Canada
Learning Objective : - Describe the significance of IDMP
- Identify the current state of IDMP implementation
- Evaluate the challenges and benefits of IDMP adoption
- Assess the readiness of regulatory bodies for IDMP
- Discuss global collaboration on IDMP implementation
- Explore practical implications of IDMP for industry
Speaker(s)
Isabel Chicharo, MPHARM
Head of Regulatory Data Management, European Medicines Agency, Netherlands
Speaker
Philipp Weyermann, DRSC, MSC
Head of Unit Regulatory Assessment 2, Swissmedic, Switzerland
Speaker
Karin Hay
Senior Policy Analyst, Health Canada, Canada
Speaker
Flávia Moreira Cruz, PHARMD
Specialist at Pharmacovigilance Officer (GFARM), ANVISA, Brazil
Speaker
Malin Fladvad, PHD, MSC
Portfolio Officer, Uppsala Monitoring Centre, Sweden
Speaker
Vada Perkins, MS
Vice President, Global Head of Regulatory Intelligence & Policy, Boehringer Ingelheim, United States
Speaker
Have an account?